Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA vs GEA in Hepatectomy for Liver Cancer
NCT07097220Completed
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine hydrochloride liposomal suspension injection in liver cancer (2 arms). Primary endpoints: Postoperative Cognitive Dysfunction at 72 hours and Postoperative Pain Intensity at 48 hours. Started May 2025; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT07097220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097220.